CollPlant Biotechnologies (NASDAQ:CLGN) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a report issued on Thursday morning,Benzinga reports. D. Boral Capital currently has a $14.00 target price on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of CollPlant Biotechnologies in a report on Friday, November 29th.

CollPlant Biotechnologies Stock Down 1.9 %

CLGN opened at $2.65 on Thursday. CollPlant Biotechnologies has a 52 week low of $2.56 and a 52 week high of $6.75. The business has a 50 day moving average price of $3.47 and a two-hundred day moving average price of $3.95. The company has a market cap of $30.36 million, a PE ratio of -1.72 and a beta of 1.07.

CollPlant Biotechnologies (NASDAQ:CLGN) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.08. CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. The business had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.36 million. As a group, sell-side analysts expect that CollPlant Biotechnologies will post -1.44 EPS for the current fiscal year.

Institutional Trading of CollPlant Biotechnologies

Several hedge funds and other institutional investors have recently made changes to their positions in CLGN. Wells Fargo & Company MN lifted its position in shares of CollPlant Biotechnologies by 110.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock valued at $30,000 after acquiring an additional 4,405 shares during the period. Renaissance Technologies LLC acquired a new position in CollPlant Biotechnologies during the fourth quarter worth $38,000. Benjamin Edwards Inc. purchased a new stake in CollPlant Biotechnologies during the third quarter worth $112,000. Finally, AMH Equity Ltd grew its holdings in CollPlant Biotechnologies by 17.4% in the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after purchasing an additional 17,295 shares during the last quarter. Institutional investors and hedge funds own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.